MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy
13 mai 2024 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis...
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy
13 mai 2024 02h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis...
MC2 Therapeutics to Present at Upcoming Conferences
26 févr. 2024 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics to Present at Upcoming Conferences Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 02h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 07h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 02h00 HE
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV
11 oct. 2023 08h15 HE
|
MC2 Therapeutics
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled...